AMG193 shows antitumor activity in MTAP-deleted solid tumors
Ben Westphalen, Chair of the Translational Research and Precision Medicine Working Group, shared a recent article by J. Rodon, on X:
“Open Access in Annals of Oncology– AMG193, a PRMT5i shows antitumor activity in MTAP-deleted solid tumors with a manageable safety. Important to apply fit for purpose molecular diagnosis to identify patients for clinical trials.”
Quoting Pashtoon Kasi ‘s post:
“From a testing standpoint, it could have been easily missed – not all testing platforms cover them.
Especially if testing was a few years ago. Worth repeating testing/knowing coverage of your panel.
Recheck the CDKN2 reports since often co-deleted with MTAP.”
Ben Westphalen reshared his views on X:
“Important point made here – in fact in the trial mentioned above – CDKN2 loss was sufficient for enrollment as the co-deletion is so frequent.”
Peter Brown, Oncology Expert, also shared his views on X:
“CDKN2 loss is indeed a significant factor.
I’ve seen this play out in trials where co-deletion is a common occurrence – it’s crucial we consider this in our research design.”
Authors: J. Rodon, H. Prenen, A. Sacher, M. Villalona-Calero, N. Penel, A. El Helali, S. Rottey, N. Yamamoto, F. Ghiringhelli, M.E. Goebeler, T. Doi, S. Postel, Vinay, C.-C. Lin, C. Liu, C.-H. Chuang, K. Keyvanjah, T. Eggert and B.H. O’Neil
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023